Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The efficacy of nilotinib treatment approaches in frontline CML

Timothy Hughes, MD, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, shares some insights into a study comparing the use of nilotinib versus a nilotinib plus imatinib switch approach for the frontline treatment of chronic myeloid leukemia (CML). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Ad boards and research support from Novartis and Takeda.